Amarin Corporation PLC (NASDAQ:AMRN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday. The firm presently has a $4.00 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective would suggest a potential upside of 15.27% from the company’s current price.

According to Zacks, “Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. “

Several other analysts also recently commented on AMRN. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Amarin Corporation PLC in a research note on Wednesday, June 28th. BidaskClub raised Amarin Corporation PLC from a “hold” rating to a “buy” rating in a research note on Friday, June 30th. ValuEngine lowered Amarin Corporation PLC from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Jefferies Group LLC raised their price objective on Amarin Corporation PLC from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, June 30th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $10.00 price objective on shares of Amarin Corporation PLC in a research note on Tuesday, September 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $7.20.

Amarin Corporation PLC (NASDAQ:AMRN) traded down 0.57% on Tuesday, hitting $3.47. The stock had a trading volume of 823,054 shares. The stock’s market capitalization is $939.65 million. The company has a 50-day moving average price of $3.24 and a 200-day moving average price of $3.32. Amarin Corporation PLC has a 52 week low of $2.65 and a 52 week high of $4.47.

Amarin Corporation PLC (NASDAQ:AMRN) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. The company had revenue of $44.95 million for the quarter, compared to the consensus estimate of $40.35 million. The firm’s revenue was up 37.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.07) earnings per share. Equities research analysts anticipate that Amarin Corporation PLC will post ($0.21) earnings per share for the current fiscal year.

WARNING: “Amarin Corporation PLC (AMRN) Rating Increased to Buy at Zacks Investment Research” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/amarin-corporation-plc-amrn-rating-increased-to-buy-at-zacks-investment-research/1606228.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AMRN. Wells Fargo & Company MN raised its position in Amarin Corporation PLC by 4.8% in the 1st quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Amarin Corporation PLC by 27.1% during the first quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 7,580 shares in the last quarter. Westside Investment Management Inc. lifted its position in shares of Amarin Corporation PLC by 1.1% during the second quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 300 shares in the last quarter. Private Advisor Group LLC boosted its holdings in Amarin Corporation PLC by 2.1% during the first quarter. Private Advisor Group LLC now owns 50,170 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 1,032 shares during the last quarter. Finally, Perkins Capital Management Inc. boosted its holdings in Amarin Corporation PLC by 20.3% during the second quarter. Perkins Capital Management Inc. now owns 41,500 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 7,000 shares during the last quarter. 37.76% of the stock is owned by institutional investors and hedge funds.

About Amarin Corporation PLC

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.